Clinical Trial Update: A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating darbepoetin alfa (NESP) for anemia in lung cancer patients undergoing multi-cycle platinum chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Cancer

Drugs mentioned

• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Amgen | Conditions: Anemia | Phase 3 | Status: COMPLETED